Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma

By | September 20, 2021
An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage IIb and IIc melanoma, according to the results of an international, randomized phase III clinical trial led by UPMC Hillman Cancer Center.